Applied Biosystems推出行業(yè)第一臺(tái)聲波聚焦流式細(xì)胞儀

Attune™聲波聚焦流式細(xì)胞儀在細(xì)胞生物學(xué)應(yīng)用中擁有更勝一籌的樣品通量、靈敏度、準(zhǔn)確性和分析速度

2009年12月7日，來自美國(guó)加利福尼亞的消息——生命技術(shù)公司（納斯達(dá)克代碼：LIFE）旗下美國(guó)應(yīng)用生物系統(tǒng)公司今日宣布它正式進(jìn)入流式細(xì)胞儀市場(chǎng)，首次推出Attune™ 聲波聚焦流式細(xì)胞儀
（Attune™Acoustic Focusing Cytometer），這是第一臺(tái)用聲波精確控制細(xì)胞移動(dòng)的流式細(xì)胞計(jì)數(shù)系統(tǒng)。該公司憑借在儀器制造上的專長(zhǎng)，再加上長(zhǎng)期以來在流式細(xì)胞儀試劑上的領(lǐng)先供應(yīng)商地位，創(chuàng)造出這種新技術(shù)新產(chǎn)品，讓客戶在一系列細(xì)胞生物學(xué)應(yīng)用中得到更高的樣品通量、靈敏度和準(zhǔn)確性。

流式細(xì)胞儀的原理在于讓細(xì)胞穿過激光檢測(cè)設(shè)備，從而使科學(xué)家們得以對(duì)細(xì)胞進(jìn)行計(jì)數(shù)和檢測(cè)。每秒鐘可計(jì)算數(shù)千個(gè)細(xì)胞的速度可實(shí)現(xiàn)對(duì)整個(gè)細(xì)胞群體的快速鑒定。流式細(xì)胞儀在細(xì)胞生物學(xué)領(lǐng)域的應(yīng)用范圍也在快速增長(zhǎng)，包括細(xì)胞表達(dá)蛋白的研究（免疫分型）、定量細(xì)胞中的DNA、細(xì)胞計(jì)數(shù)及其它。

Attune聲波聚焦流式細(xì)胞儀可幫助科學(xué)家們實(shí)現(xiàn)對(duì)細(xì)胞群體中大量異質(zhì)細(xì)胞進(jìn)行統(tǒng)計(jì)學(xué)數(shù)據(jù)的采集，以便研究包括大小、復(fù)雜性、表型和健康情況在內(nèi)的細(xì)胞群體參數(shù)。Attune的專利技術(shù)可讓科學(xué)家們獲得更高的靈敏度，通過增加通量來節(jié)約時(shí)間，并可用于體積小的樣品。此外，Attune在提供這些升級(jí)性能的同時(shí)，還憑借緊湊的聲學(xué)技術(shù)而實(shí)現(xiàn)了體積小，以及開展實(shí)驗(yàn)所需的消耗品量更少等優(yōu)勢(shì)。這些獨(dú)特的特征將有助于實(shí)現(xiàn)傳統(tǒng)細(xì)胞儀系統(tǒng)所無法實(shí)現(xiàn)的科研應(yīng)用，從樣品分離制備到微珠為基礎(chǔ)的樣品分析。

生命科技公司細(xì)胞系統(tǒng)的總裁Nicolas Barthelemy 表示： “Attune技術(shù)將某些實(shí)驗(yàn)的時(shí)間縮短了一個(gè)數(shù)量級(jí)并大大提高了靈敏度，從而加速了研究流程�！薄斑@種獨(dú)特儀器的推出，正是生命技術(shù)公司綜合利用世界頂級(jí)儀器制造經(jīng)驗(yàn)和細(xì)胞生物學(xué)上的專長(zhǎng)，為生命科學(xué)研究者推出創(chuàng)新技術(shù)方案的又一范例。此儀器非常適合細(xì)胞信號(hào)分析和靈敏度極其重要的稀有細(xì)胞學(xué)應(yīng)用，它也是各種細(xì)胞分析實(shí)驗(yàn)室的極好補(bǔ)充�！�

生命科技公司流式細(xì)胞儀的主管Mike Olszowy表示：“在流式細(xì)胞儀方面，聲學(xué)聚焦技術(shù)同時(shí)實(shí)現(xiàn)了更長(zhǎng)的通過時(shí)間和更高的通量，因而能夠在對(duì)樣品中每一個(gè)細(xì)胞進(jìn)行更好分析的同時(shí)對(duì)更大量的細(xì)胞進(jìn)行分析。Attune的推出使得生命科技公司朝著‘?dāng)?shù)字生物學(xué)’的藍(lán)圖又邁進(jìn)了一步，憑借‘?dāng)?shù)字生物學(xué)’科學(xué)家們將跨越異質(zhì)細(xì)胞混合群體的整體分析而推進(jìn)到在單細(xì)胞水平對(duì)分子表型進(jìn)行更為精確的定量分析�！�

生命科技公司（納斯達(dá)克代碼：LIFE）是一家致力于改善人類環(huán)境的全球生物技術(shù)公司。我們的儀器、耗材和服務(wù)能讓研究者加速科學(xué)探索與開發(fā)，讓生命變得更美好。我們的客戶在生物學(xué)領(lǐng)域努力工作，不斷加速個(gè)性化藥物、再生科學(xué)、分子診斷、農(nóng)業(yè)和環(huán)境研究以及21世紀(jì)的法醫(yī)鑒定。公司2008年的銷售額超過30億，全球雇員達(dá)9500人，分布在100多個(gè)國(guó)家，并擁有3600多項(xiàng)知識(shí)產(chǎn)權(quán)專利及專有許可證。生命科技公司由Invitrogen公司和應(yīng)用生物系統(tǒng)公司合并而成。更多關(guān)于我們?nèi)绾纹鹱饔玫男畔ⅲ��?qǐng)?jiān)L問網(wǎng)站http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2 www.lifetechnologies.com&esheet=6114661&lan=en_US&anchor www.lifetechnologies.com&index=1&md5=72d77b8670b362b20a1b9b112bbd708f。在Facebook和Twitter上追隨生命科技公司（@LIFECorporation）。

本新聞稿包含前瞻性聲明，涉及帶有風(fēng)險(xiǎn)與不確定性的預(yù)期結(jié)果。本新聞稿中所包含的某些信息，包括但不限于，行業(yè)趨勢(shì)和生命科技公司的計(jì)劃、目標(biāo)、預(yù)期和其商業(yè)策略的陳述，可能導(dǎo)致的實(shí)際結(jié)果與前瞻性聲明中明示或暗示的風(fēng)險(xiǎn)和不確定性將存在差異。任何聲明都不是歷史事實(shí)的陳述，而是前瞻性聲明。在措辭上，使用“相信”、“計(jì)劃”、“試圖”、“預(yù)期”、“制定目標(biāo)”、“估計(jì)”、“期望”等，并/或使用將來時(shí)或條件結(jié)構(gòu)句（“將”、“可能”、“能夠”、“應(yīng)該”等），或類似的表述可分辨出某些前瞻性聲明。那些可能導(dǎo)致實(shí)際結(jié)果與這些前瞻性聲明中的描述大相徑庭的重要因素，在生命科技公司提交給美國(guó)證券交易委員會(huì)的各種文件中有詳細(xì)說明。生命科技公司不承擔(dān)更新或修訂任何前瞻性聲明的義務(wù)，以反映后期事件或環(huán)境。

來源：生命科技公司

Applied Biosystems Debuts Industry's First Acoustic Flow Cytometer

CARLSBAD, Calif., Dec 07, 2009 (BUSINESS WIRE) -- Applied Biosystems, part of LifeTechnologies Corporation (NASDAQ:LIFE) today announced its entry into the flow cytometry instrumentation market with the debut of the Attune(TM) Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells. The company has built upon its expertise in instrumentation, as well as its position as a long-time leading provider of flow cytometry reagents, to create a technology that will offer customers enhanced sample throughput, sensitivity and accuracy for a range of cell biology applications.

Flow cytometry allows scientists to count and examine cells by passing them through a laser-based detection device. Thousands of cells per second may be counted, allowing rapid characterization of entire populations of cells. Cellular biologists engage in flow cytometry for a rapidly growing range of applications, including the study of proteins expressed by cells (immunophenotyping), quantifying the amount of DNA in cells, cell counting, among others.

Attune enables scientists to gather statistical data on a large number of heterogeneous cells to study parameters within a cell population, including size, complexity, phenotype and health. Attune's proprietary technology allows scientists to achieve enhanced sensitivity, saves time by increasing throughput, and can be used with small sample sizes. In addition, it offers these enhanced capabilities with a reduced footprint due to the compact acoustic technology and the far smaller volume of consumables required to perform an experiment. These unique capabilities will enable scientific applications not previously possible on traditional cytometry systems, ranging from sample preparation to bead-based analyses.

"The Attune technology will accelerate research workflows by reducing the time of some experiments by an order of magnitude with greatly increased sensitivity," said Nicolas Barthelemy, President of Cell Systems at Life Technologies. "The introduction of this unique instrument is another example of how Life Technologies is using its expertise in both world-class instrumentation and cell biology to create an innovative solution for life science researchers. This instrument is ideally suited for cell signaling and rare event applications where sensitivity is critical and is a great addition to any cellular analysis laboratory."

"In flow cytometry, acoustic focusing enables both longer transit times and higher throughput, which simultaneously permits better interrogation of every cell in a sample as well as the analysis of much larger numbers of cells," said Mike Olszowy, Head of Flow Cytometry at Life Technologies. "The introduction of Attune brings Life Technologies one step closer to its vision of 'Digital Biology' whereby scientists can move beyond ensemble measurements of heterogeneous mixtures to a more precise quantitation of molecular phenotypes at the single cell level."

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2 www.lifetechnologies.com&esheet=6114661&lan=en_US&anchor www.lifetechnologies.com&index=1&md5=72d77b8670b362b20a1b9b112bbd708f. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

SOURCE: Life Technologies Corporation